Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP1997/002240external-prioritypatent/WO1998055139A1/en
Application filed by Smithkline Beecham PlcfiledCriticalSmithkline Beecham Plc
Priority to NO995940ApriorityCriticalpatent/NO995940L/en
Publication of NO995940D0publicationCriticalpatent/NO995940D0/en
Publication of NO995940LpublicationCriticalpatent/NO995940L/en
Anvendelse av en leptin-antagonist for fremstilling av et medikament for behandling av lidelser som er et resultat av svikt i insulinsekresjon, hyperglykemi og insulinresistens.Use of a leptin antagonist for the manufacture of a medicament for the treatment of disorders resulting from failure in insulin secretion, hyperglycemia and insulin resistance.
NO995940A1997-06-061999-12-03
Use of leptin antagonists for the treatment of diabetes
NO995940L
(en)
Selective estrogen receptor modulators in the treatment or reduction of the risk of acquiring hypertension, cardiovascular diseases, and insulin resistance
Use of saredutant and pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment or prevention of mood disorders, adaptive disorders, or mixed anxiety depressive disorders.
NEW COMBINATION FROM REVERSIBLE ACTING PROTONE PUMP INHIBITORS AND USED IN THE THERAPY OF RESPIRATORY WAYS OF MEDICINAL SUBSTANCES FOR THE TREATMENT OF RESPIRATORY DISEASES